GLP-1 agonists reduce major cardiac events in type 2 diabetes

Largest study of pooled data shows the drugs cut major CV events by 12% and MI by 9%
Reuters Health
cardioprotective drugs

Major adverse cardiovascular and renal events are reduced in patients with type 2 diabetes whose treatment includes GLP-1 receptor agonists, according to findings from the largest study of pooled data to date.

The systematic review and meta-analysis of seven trials covering 56,000 people showed that cardiovascular (CV) and all-cause deaths were reduced among those taking the antihyperglycaemics.